Do analysts agree on Kempharm (kmph) stock's price target?
KemPharm (NASDAQ:KMPH) Price Target and Consensus Rating 2 Wall Street analysts have issued ratings and price targets for KemPharm in the last 12 months. Their average twelve-month price target is $12.00, predicting that the stock has a possible upside of 17.19%. The high price target for KMPH is $12.00 and the low price target for KMPH is $12.00.
How much did kmph raise in its IPO?
(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
What is the marketbeat consensus rating for Kempharm?
The consensus rating score for KemPharm is 2.50 while the average consensus rating score for medical companies is 2.72. Learn more Do MarketBeat users like KemPharm more than its competitors?
Should I buy KemPharm stock?
Is Kempharm Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: KMPH) stock is to Buy KMPH stock.
What is the long range forecast for KMPH stock?
KemPharm Inc quote is equal to 5.350 USD at 2022-07-19. Based on our forecasts, a long-term increase is expected, the "KMPH" stock price prognosis for 2027-07-14 is 18.628 USD. With a 5-year investment, the revenue is expected to be around +248.19%. Your current $100 investment may be up to $348.19 in 2027.
Why did KMPH drop?
What happened. Shares of KemPharm (KMPH 3.78%) were sinking 12.6% as of 3:33 p.m. EDT on Friday. The big drop came after the drugmaker announced the exercise of existing warrants and the issuance of new warrants.
Is NLOK a buy or sell?
Is Nortonlifelock Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: NLOK) stock is to Hold NLOK stock.
Will KemPharm go up?
The 2 analysts offering 12-month price forecasts for KemPharm Inc have a median target of 19.50, with a high estimate of 28.00 and a low estimate of 11.00. The median estimate represents a +333.33% increase from the last price of 4.50.
Is TFFP a buy?
Is Tff Pharmaceuticals Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: TFFP) stock is to Strong Buy TFFP stock.
How do you buy stocks on wish?
Shares of WISH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Why is NLOK stock down?
NortonLifeLock stock was dropping Tuesday after the online security software provider was downgraded by Morgan Stanley on concerns over slowing growth. Analyst Hamza Fodderwala cut his rating on NortonLifeLock (ticker: NLOK ) to Equal-weight from Overweight, while maintaining his $28 price target.
Will NortonLifeLock stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for NortonLifeLock Inc have a median target of 26.50, with a high estimate of 29.00 and a low estimate of 25.90. The median estimate represents a +5.92% increase from the last price of 25.02.
How much is Norton stock worth?
$ 24.73CloseChgChg %$24.730.040.16%
Is Medifast a good stock to buy?
Valuation metrics show that MEDIFAST INC may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of MED, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
Is mimecast a buy?
Mimecast has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on 4 buy ratings, 13 hold ratings, and no sell ratings.
Is Norton a LifeLock?
LifeLock By Norton combines the recognized Norton computer and online security name with LifeLock's reputation as a known player in identity theft protection.
Is Norton Antivirus publicly traded?
NortonLifeLock Inc. Sunnyvale, California, U.S. U.S. On October 9, 2014, Symantec declared it would split into two independent publicly traded companies by the end of 2015.
Should I buy or sell KemPharm stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 buy rating for t...
What is KemPharm's stock price forecast for 2022?
1 equities research analysts have issued 1 year price objectives for KemPharm's stock. Their forecasts range from $11.00 to $11.00. On average, the...
How has KemPharm's stock price performed in 2022?
KemPharm's stock was trading at $8.71 at the beginning of 2022. Since then, KMPH stock has decreased by 49.5% and is now trading at $4.40. View th...
When is KemPharm's next earnings date?
KemPharm is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for KemPharm .
How were KemPharm's earnings last quarter?
KemPharm, Inc. (NASDAQ:KMPH) posted its quarterly earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08)...
Who are KemPharm's key executives?
KemPharm's management team includes the following people: Mr. Richard W. Pascoe , Exec. Chairman (Age 58, Pay $515.43k) ( LinkedIn Profile ) Dr....
Who are some of KemPharm's key competitors?
Some companies that are related to KemPharm include Kiniksa Pharmaceuticals (KNSA) , Repare Therapeutics (RPTX) , Foghorn Therapeutics (FHTX) ,...
What other stocks do shareholders of KemPharm own?
Based on aggregate information from My MarketBeat watchlists, some companies that other KemPharm investors own include Sorrento Therapeutics (SRNE...
When did KemPharm IPO?
(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen...
How much is KemPharm stock worth in 2021?
Does KemPharm have a sell signal?
The KemPharm stock price gained 2.13% on the last trading day (Thursday, 8th Jul 2021), rising from $12.69 to $12.96. During the day the stock fluctuated 6.89% from a day low at $12.20 to a day high of $13.04. The price has fallen in 7 of the last 10 days and is down by -9.37% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 161 thousand more shares were traded than the day before. In total, 536 thousand shares were bought and sold for approximately $6.95 million.
Is KemPharm a sell candidate?
Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
What is KMPH in 2021?
KemPharm holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate ( hold or accumulate) in this position whilst awaiting further development.
How much is KemPharm's net loss for Q1 2021?
(NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietar y prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placeme
Is KemPharm a Russell 3000?
Current consulting arrangements contractually continue through March 2022. KemPharm’s net loss for Q1 2021 was $10.3 million, or $0.54 per basic share and diluted share, compared to net loss of $5.8 million, or $1.92 per basic and diluted share for the same period in 2020.
When is KemPharm's earnings call 2021?
CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution. KemPharm’s anticipated inclusion in the Russell indexes will be effective after the U.S. market opens on Monday, June 28, 2021. "The expected
When is KemPharm's quarterly report due 2021?
(NASDAQ:KMPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
Is KP879 a Schedule IV drug?
Risks concerning KemPharm’s business are described in detail in KemPharm’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, and KemPharm’s other filings with the Securities and Exchange Commission.
Is KemPharm under any obligation?
If approved, KP879 could be a Schedule IV product, and physicians who are treating patients seeking to overcome addictions to cocaine, methamphetamine or other stimulants may be able to prescribe KP879 with the knowledge that the product candidate could have a significantly lower potential for abuse.”.
What is KemPharm GPC?
KemPharm is under no obligation to, and expressly disclaim s any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. KemPharm Contacts: Jason Rando / Maureen McEnroe, CFATiberend Strategic Advisors, Inc. (212) 375-2665 / [email protected]@tiberend.com.
Is KemPharm gaining interest on Twitter?
KemPharm Inc (NASDAQ: KMPH) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to d...
KemPharm (NASDAQ:KMPH) Price Target and Consensus Rating
KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME). The post KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Sque...
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
KemPharm (NASDAQ:KMPH) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
KMPH Stock Trend
According to the issued ratings of 1 analysts in the last year, the consensus rating for KemPharm stock is Buy based on the current 1 buy rating for KMPH. The average twelve-month price target for KemPharm is $11.00 with a high price target of $11.00 and a low price target of $11.00. Learn more on KMPH's analyst rating history
About KemPharm
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Golden Star Signal
KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its advanced product candidate is KP201/APAP, which consists of KP201 prodrug of hydrocodone formulated in combination with acetaminophen (APAP).
